Investigators find the recognition could improve surveillance of the disease.
An investigation of progression of primary open-angle glaucoma (POAG) identified 5 potential candidate biomarkers in the aqueous humor related to the glaucomatous phenotypes that differentiate stable from progressive cases of glaucoma.
Although it is known that glaucoma is a progressive optic neuropathy that results from a combination of genetic and environmental factors, there is not a great deal of information about the genetic risks associated with development of the disease.
Mengya Zhao, PhD , with the Department of Ophthalmology at the University of California, San Francisco, compared the gene expression profiles between patients with stable POAG and patients requiring glaucoma surgery to address POAG.
According to Zhao, 21 transcripts were differentially expressed between the study groups: 20 were upregulated and 1 was downregulated in the patients with progressive POAG compared with those with stable glaucoma. Eleven of the transcripts were eye-related, and 5 transcripts were related to the following glaucomatous phenotypes: fibronectin type III domain containing 3B (FNDC3B), clusterin (CLU), proprotein convertase subtilisin/kexin type 6 (PCSK6), cadherin EGF LAG seven-pass G-type receptor 1 (CELSR1), and rho guanine nucleotide exchange factor 4 (ARHGEF4).
The following connections to glaucoma were mentioned for the phenotypes:
The key factors identified in the study, the investigators concluded, are that biomarkers associated with POAG progression were identified and that it is possible to identify the biomarkers from aqueous humor samples.
Importantly, the recognition of the biomarkers may improve glaucoma surveillance of patients with progressive POAG, as well as provide diagnostic and therapeutic targets to identify and treat progressive POAG early.